Arrowhead Pharmaceuticals Director Sells 11,600 Shares

According to an SEC Form 4 filing, Michael S. Perry, a Director at Arrowhead Pharmaceuticals, sold 11,600 shares of common stock on August 18, 2026. The shares were disposed of in multiple transactions at prices ranging from $87.20 to $87.44, with a transaction value based on a weighted average sale price of $87.30.

By selling 11,600 shares, the director liquidated 9% of his direct holdings. However, he remains a stakeholder with 0.0791% of the company's equity and continues to hold common stock underlying unvested restricted stock units.

Arrowhead Pharmaceuticals, headquartered in Pasadena, California, is a clinical-stage biopharmaceutical company developing therapeutics leveraging RNA interference technology. The company reported trailing twelve-month revenue of $669.5 million, a net loss of $320 million, and maintains a market capitalization of $12.2 billion.